EICHOR
● Active Not Recruiting
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Condition: Recurrent Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Sponsor: National Cancer Institute (NCI)
About this study
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (296)
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| University of South Alabama Mitchell Cancer Institute | Mobile, Alabama, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| CTCA at Western Regional Medical Center | Goodyear, Arizona, United States | — |
| Kingman Regional Medical Center | Kingman, Arizona, United States | — |
| PCR Oncology | Arroyo Grande, California, United States | — |
| Cedars-Sinai Medical Center | Los Angeles, California, United States | — |
| Saint Joseph Hospital - Orange | Orange, California, United States | — |
| Stanford Cancer Institute Palo Alto | Palo Alto, California, United States | — |
| Presbyterian Intercommunity Hospital | Whittier, California, United States | — |
| UM Sylvester Comprehensive Cancer Center at Aventura | Aventura, Florida, United States | — |
| UM Sylvester Comprehensive Cancer Center at Coral Gables | Coral Gables, Florida, United States | — |
+ 284 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05554328